

Appendix 4E Preliminary final report

Rule 4.3A
Introduced 1/1/2003

Name of Entity: Chrysos Corporation Limited
ABN: 76 613 131 141

1. Reporting period ("current period"): Year ended 30 June 2024
Previous corresponding period: Year ended 30 June 2023

2. Results for announcement to the market:

				\$A'000
Revenue	up	69%	to	45,361
Profit / (loss) from ordinary activities after tax attributable to shareholders	down	-	to	(704)
Net profit / (loss) for the period attributable to shareholders	down	-	to	(704)

Dividends	Amount per share cents	Franked amount per share cents
Final	-	-
Interim	-	-

Record date for determining entitlements to dividends: N/A

Brief explanation of figures 2.1 to 2.4 (if necessary):
N/A

3. Condensed consolidated income statement

	Current Period	Previous corresponding period
	\$A'000	\$A'000
PhotonAssay™ Income	44,178	25,613
Revenue from Consumables	1,183	1,204
Other Income	2,805	1,591
PhotonAssay Expenses	(10,120)	(5,171)
Employee benefit expenses	(15,587)	(10,988)
Consulting and advisory	(1,235)	(985)
Consumables cost of sales	(822)	(1,085)
Travel and marketing costs	(2,131)	(1,490)
IT Costs	(1,592)	(815)
Legal fees	(817)	(398)
Other Expenses	(4,107)	(2,385)
Depreciation and amortisation expense	(11,439)	(6,421)
Finance Costs	(1,996)	(792)
Profit / (loss) before income tax expense	(1,680)	(2,122)
Income tax expense	976	2,565
Profit / (loss) from continuing operations	(704)	443
Profit / (loss) from discontinued operations	-	-
Profit / (loss) for the period	(704)	443
Net profit / (loss) attributable to minority interest	-	-
Profit / (loss) attributable to shareholders of the parent entity	(704)	443
Revenue & Other Income		
PhotonAssay™ Income		
PhotonAssay™ Income – minimum lease payments	39,494	21,336
PhotonAssay™ Income – variable lease payments	4,684	4,277
	44,178	25,613
Revenue from PhotonAssay™	1,183	1,204
Other Income		
Government Grants	25	-
Gains / (losses) on foreign currency	-	-
Interest	2,780	1,591
	2,805	1,591

Expenses:

Loss before income tax includes the following specific expenses:

Depreciation		
Plant & Equipment	583	370
Deployed Units	10,065	5,694
	10,648	6,064
Right of use assets	505	175
	11,153	6,239
Amortisation		
Intellectual Property	286	182
	286	182
Total Depreciation and Amortisation	11,439	6,421
Finance Costs		
Interest and finance charges paid/payable on other liabilities	1,923	753
Interest and finance charges paid/payable on lease liabilities	-	-
(Gains)/Losses on Foreign Exchange	73	39
Finance costs expensed	1,996	792
Short term lease payments	-	-
Superannuation on defined contribution funds	1,261	805

4. Condensed Consolidated balance sheet:

	Current Period	Previous corresponding period
	\$A'000	\$A'000
CURRENT ASSETS		
Cash and cash equivalents	61,067	53,359
Trade and other receivables	16,405	8,504
Research & development receivable	1,649	1,460
Other Current assets	964	1,052
Prepayments	14,299	5,631
TOTAL CURRENT ASSETS	94,384	70,006
 NON-CURRENT ASSETS		
Property, Plant & Equipment	135,935	86,734
Right of use assets	2,187	574
Intangible assets	4,178	2,463
Deferred Tax Asset	6,581	3,633
TOTAL NON-CURRENT ASSETS	148,881	93,404
TOTAL ASSETS	243,265	163,410
 CURRENT LIABILITIES		
Trade and other payables	35,880	22,432
Lease liabilities	214	145
Employee benefits	2,165	2,290
Other financial liabilities	-	622
Provisions	83	55
TOTAL CURRENT LIABILITIES	38,342	25,544
 NON-CURRENT LIABILITIES		
Lease Liabilities	2,432	307
Employee benefits	196	130
Other financial liabilities	4,021	4,748
Loans and Borrowings	-	8,454
TOTAL NON-CURRENT LIABILITIES	6,649	13,639
 TOTAL LIABILITIES	44,991	39,183
 NET ASSETS	198,274	124,227
 EQUITY		
Issued Capital	210,660	136,043
Other reserves	(14,788)	(14,084)
Accumulated losses	2,402	2,268
TOTAL EQUITY	198,274	124,227

5. Condensed consolidated statement of cash flows

	Current Period	Previous corresponding period
	\$A'000	\$A'000
Net Cash flows from operating activities		
Receipts from customers (inclusive of GST)	35,165	26,085
Payments to suppliers & employees (inclusive of GST)	(33,375)	(21,883)
Research and development refund received	-	-
Interest paid	(1,347)	(1,140)
Interest received	3,161	1,591
Government Grants	25	-
Net cash provided / (used in) operating activities	3,629	4,653
 Cash flows from investing activities		
Purchases of intangibles	(2,095)	(1,268)
Purchases of property, plant and equipment	(57,768)	(45,995)
Net cash provided / (used in) investing activities	(59,863)	(47,263)
 Cash flows from financing activities		
Proceeds from issue of share capital	76,948	317
Transaction costs of issue of share capital	(3,628)	-
Proceeds from borrowings	-	8,454
Repayment of lease liabilities	(567)	(327)
Repayment of borrowings	(8,454)	(4,900)
Net cash provided / (used in) financing activities	64,299	3,544
 Net increase / (decrease) in cash & cash equivalents	 8,065	 (39,065)
 Cash & cash equivalents at the beginning of the financial period	 53,359	 92,104
Effects of exchange rate changes on the balance of cash & cash equivalents in foreign currencies	(357)	321
Cash & cash equivalents at the end of the financial period	61,067	53,359

6. Dividends

		Amount per security	Franked amount per security at 30% tax	Amount per security of foreign source dividend
		Cents	Cents	Cents
Final Dividend	Current year	-	-	-
	Previous year	-	-	-
Interim Dividend	Current year	-	-	-
	Previous year	-	-	-

Total Dividends on all securities for the year

	Current period	Previous corresponding period
Ordinary securities	115,033,797	99,590,770
Preference securities	-	-
Other equity instruments	-	-
Total	115,033,797	99,590,770

7. Dividend reinvestment plans

The dividend reinvestment plans shown below are in operation:

None

Last date for receipt of election notices for the dividend reinvestment plan: N/A

8. Retained Earnings

	Current period	Previous corresponding period
	\$'000	\$'000
(Accumulated Losses) at beginning of financial period	(14,084)	(14,527)
Net profit / (loss) attributable to members	(704)	443
(Accumulated Losses) at end of financial period	(14,788)	(14,084)

9. Net Tangible Assets

	Current period	Previous corresponding period
	\$	\$
Net tangible asset backing per ordinary share	1.63	1.18

10. Details of entities which control has been gained or lost

Chrysos Corporation Limited has the following 100% wholly owned subsidiaries in which were incorporated during the financial period:

- Chrysos Leasing Pty Ltd (Incorporated in Australia and on 23 November 2023)
- PhotonAssay Pty Ltd (Incorporated in Australia and on 23 November 2023)
- PhotonAssay Burkina Pty Ltd (Incorporated in Australia and on 12 January 2024)
- PhotonAssay International Pty Ltd (Incorporated in Australia and on 28 March 2024)
- Chrysos Guinea SARU (Incorporated in Guinea and on 4 August 2023)
- Chrysos KSA Pty Ltd (Incorporated in Australia and on 10 October 2023)
- Chrysos UK Services Limited (Incorporated in United Kingdom and on 16 August 2023)

11. Details of associates and joint venture entities

N/A

12. Any other significant information

N/A

13. Accounting Standards

The financial report is a general-purpose financial report that has been prepared in accordance with Australian Accounting Standards (including Australian Accounting Interpretations) other authoritative pronouncements of the Australian Accounting Standards board and the Corporations Act 2001.

14. Results for the period

14.1. Earnings per security

	Current period	Previous corresponding period
	Cents	Cents
Basic earnings per share	(0.65)	0.5
	Number	Number
Weighted average number of ordinary shares outstanding during the period used in the calculation of basic EPS	108,746,876	98,663,955

14.2. Returns to shareholders

N/A

14.3. Significant features of operating performances

Continued growth due to deployment of PhotonAssay™ Max Units.

14.4. Segment Results

	Current period	Previous corresponding period
	\$'000	\$'000
Segment Revenues		
Australia	20,326	18,701
Middle East & Africa	17,339	5,573
Americas	7,696	2,543
Total Revenues	45,361	26,817
Segment Depreciation & Amortisation		
Australia	4,499	4,634
Middle East & Africa	3,120	1,023
Americas	2,443	764
Total of segments Depreciation & Amortisation	10,062	6,421
Segment Results: Profit before tax		
Australia	11,618	10,937
Middle East & Africa	10,321	2,047
Americas	2,685	318
Total of segments	24,624	13,302
Reconciliation of reportable segment to profit / (loss) before tax		
Segment profit	24,624	13,302
Central Costs	(26,304)	(15,424)
Profit / (Loss) before tax	(1,680)	(2,122)
Income tax benefit / (expense)	976	2,565
Comprehensive profit / (loss) for the period	(704)	443
Segment Capital Expenditure		
Australia	-	15,977
Middle East & Africa	19,828	11,040
Americas	15,364	7,561

	Assets		Liabilities	
	Current period	Previous corresponding period	Current period	Previous corresponding period
	\$'000	\$'000	\$'000	\$'000
Australia - Current	2,669	4,107	-	622
Australia – Total	25,654	35,659	898	4,747
Middle East & Africa – Current	8,671	2,279	-	-
Middle East & Africa – Total	46,238	15,894	531	-
Americas – Current	3,780	2,672	-	-
Americas – Total	30,267	17,129	2,592	-
Total of Segments	102,159	68,682	4,021	4,747
Unallocated	141,106	94,728	40,970	34,436
Total	243,265	163,410	44,991	39,183

14.5. Trends in performance
Revenue below guidance range, EBITDA within range.

14.6. Any other factors which have affected the results in the period which are likely to affect the result in the future, including those where the effect could not be quantified

N/A

15. This report is based on accounts to which one of the following applies

- The accounts have been audited
- The accounts have been subject to review
- The accounts are in the process of being audited or subject to review
- The accounts have not been audited or reviewed

16. Description of any likely audit dispute or qualification

N/A

Sign here:


Company Director
Dirk Moore Treasure

Date: 27 August 2024